Yesterday, Reglagene was featured in a webinar hosted by Cancer Fund. We were proud to be their featured company. The audience got to learn more about Cancer Fund, and be introduced to Reglagene’s CEO Richard Austin, Business Development Manager Michael Abrahamson, and their newly elected Board Director, David Bearss. We thank Cancer Fund for this opportunity and want to thank all the participants who attended the event!
Reglagene is delighted to announce that its shareholders elected David Bearss, PhD, as Director. Dr. Bearss is a drug development expert. He has led teams that discovered 15 cancer medicines for which Initial New Drug applications were filed at the FDA, leading to human clinical trials. Dr. Bearss is a successful bioentrepreneur with several exits. As founder and CEO of Tolero Pharmaceuticals, he led its acquisition by Sumitomo Dainippon in 2017 for $780mm. Dr. Bearss' talents and contributions will accelerate Reglagene's timelines to advancing new cancer medicines into human clinical trials.